{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:47:08Z","timestamp":1785548828500,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40121-022-00720-x","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:17:13Z","timestamp":1669310233000},"page":"193-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftolozane\u2013Tazobactam Pharmacokinetics in the Abdominal Tissue of Patients Undergoing Lower Gastrointestinal Surgery: Dosing Considerations Based on Site-Specific Pharmacodynamic Target Attainment"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-1109","authenticated-orcid":false,"given":"Kosuke","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Uegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Watadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kaiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"720_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et\u00a0al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133\u201364. https:\/\/doi.org\/10.1086\/649554.","journal-title":"Clin Infect Dis"},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/jac\/dkx146","volume":"72","author":"ER Bevan","year":"2017","unstructured":"Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M \u03b2-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother. 2017;72:2145\u201355. https:\/\/doi.org\/10.1093\/jac\/dkx146.","journal-title":"J Antimicrob Chemother"},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"e01093","DOI":"10.1128\/JCM.01093-17","volume":"56","author":"RK Shields","year":"2018","unstructured":"Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, et\u00a0al. Verification of ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018;56:e01093-e1117. https:\/\/doi.org\/10.1128\/JCM.01093-17.","journal-title":"J Clin Microbiol"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1060028014556652","volume":"49","author":"KA Toussaint","year":"2015","unstructured":"Toussaint KA, Gallagher JC. \u03b2-Lactam\/\u03b2-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015;49:86\u201398. https:\/\/doi.org\/10.1177\/1060028014556652.","journal-title":"Ann Pharmacother"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"e02125","DOI":"10.1128\/AAC.02125-17","volume":"62","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of ceftolozane\u2013tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. Antimicrob Agents Chemother. 2018;62:e02125-e2217. https:\/\/doi.org\/10.1128\/AAC.02125-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1128\/AAC.01590-12","volume":"57","author":"WA Craig","year":"2013","unstructured":"Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57:1577\u201382. https:\/\/doi.org\/10.1128\/AAC.01590-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jac\/dks343","volume":"68","author":"C Jacqueline","year":"2013","unstructured":"Jacqueline C, Roquilly A, Desessard C, Boutoille D, Broquet A, Le Mabecque V, et\u00a0al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother. 2013;68:177\u201383. https:\/\/doi.org\/10.1093\/jac\/dks343.","journal-title":"J Antimicrob Chemother"},{"key":"720_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jac\/dkx009","volume":"72","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315). J Antimicrob Chemother. 2017;72:1386\u201395. https:\/\/doi.org\/10.1093\/jac\/dkx009.","journal-title":"J Antimicrob Chemother"},{"key":"720_CR9","doi-asserted-by":"publisher","first-page":"e00465","DOI":"10.1128\/AAC.00465-17","volume":"61","author":"D Shortridge","year":"2017","unstructured":"Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane\u2013tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2017;61:e00465-17. https:\/\/doi.org\/10.1128\/AAC.00465-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et\u00a0al. Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462\u201371. https:\/\/doi.org\/10.1093\/cid\/civ097.","journal-title":"Clin Infect Dis"},{"key":"720_CR11","unstructured":"FDA. FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia; 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia Accessed 9 February 2020"},{"key":"720_CR12","doi-asserted-by":"publisher","first-page":"e02578","DOI":"10.1128\/AAC.02578-18","volume":"63","author":"KB Larson","year":"2019","unstructured":"Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, et\u00a0al. Ceftolozane\u2013tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra-abdominal infections. Antimicrob Agents Chemother. 2019;63:e02578-e2618. https:\/\/doi.org\/10.1128\/AAC.02578-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcph.1733","volume":"61","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Patel YT, Fiedler-Kelly J, Feng HP, Bruno CJ, Gao W. Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane\/tazobactam concentrations in patients with ventilated nosocomial pneumonia. J Clin Pharmacol. 2021;61:254\u201368. https:\/\/doi.org\/10.1002\/jcph.1733.","journal-title":"J Clin Pharmacol"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","volume":"21","author":"I Kobayashi","year":"2015","unstructured":"Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, et\u00a0al. Penetration of piperacillin\u2013tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015;21:575\u201380. https:\/\/doi.org\/10.1016\/j.jiac.2015.04.015.","journal-title":"J Infect Chemother"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijantimicag.2007.04.012","volume":"30","author":"K Ikawa","year":"2007","unstructured":"Ikawa K, Morikawa N, Hayato S, Ikeda K, Ohge H, Sueda T. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents. 2007;30:270\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.04.012.","journal-title":"Int J Antimicrob Agents"},{"key":"720_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.06.001","volume":"30","author":"K Ikawa","year":"2007","unstructured":"Ikawa K, Morikawa N, Matsuda S, Ikeda K, Ohge H, Takesue Y, et\u00a0al. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. Int J Antimicrob Agents. 2007;30:352\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.06.001.","journal-title":"Int J Antimicrob Agents"},{"key":"720_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijantimicag.2017.03.025","volume":"50","author":"N Murao","year":"2017","unstructured":"Murao N, Ohge H, Ikawa K, Watadani Y, Uegami S, Shigemoto N, et\u00a0al. Pharmacokinetics of piperacillin\u2013tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment. Int J Antimicrob Agents. 2017;50:393\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.025.","journal-title":"Int J Antimicrob Agents"},{"key":"720_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/chromsci\/bmw047","volume":"54","author":"CA Sutherland","year":"2016","unstructured":"Sutherland CA, Nicolau DP. Development of an HPLC method for the determination of ceftolozane\/tazobactam in biological and aqueous matrixes. J Chromatogr Sci. 2016;54:1037\u201340. https:\/\/doi.org\/10.1093\/chromsci\/bmw047.","journal-title":"J Chromatogr Sci"},{"key":"720_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4155\/bio-2017-0257","volume":"10","author":"C Ezquer-Garin","year":"2018","unstructured":"Ezquer-Garin C, Ferriols-Lisart R, Al\u00f3s-Almi\u00f1ana M, Aguilar-Aguilar G, Belda-Nacher JF, Carbonell JA. Validated HPLC\u2013UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma. Bioanalysis. 2018;10:461\u201373. https:\/\/doi.org\/10.4155\/bio-2017-0257.","journal-title":"Bioanalysis"},{"key":"720_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1248\/bpb1978.4.879","volume":"4","author":"K Yamaoka","year":"1981","unstructured":"Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4:879\u201385. https:\/\/doi.org\/10.1248\/bpb1978.4.879.","journal-title":"J Pharmacobiodyn"},{"key":"720_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijantimicag.2013.08.016","volume":"43","author":"AM Barbour","year":"2014","unstructured":"Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H. Application of pharmacokinetic\/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time\u2013kill curve based approaches. Int J Antimicrob Agents. 2014;43:60\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.08.016.","journal-title":"Int J Antimicrob Agents"},{"key":"720_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jiac.2021.03.010","volume":"27","author":"T Ueda","year":"2021","unstructured":"Ueda T, Takesue Y, Matsumoto T, Tateda K, Kusachi S, Mikamo H, et\u00a0al. Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study. J Infect Chemother. 2021;27:931\u20139. https:\/\/doi.org\/10.1016\/j.jiac.2021.03.010.","journal-title":"J Infect Chemother"},{"key":"720_CR24","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1128\/AAC.03572-14","volume":"58","author":"AJ Lepak","year":"2014","unstructured":"Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother. 2014;58:6311\u20134. https:\/\/doi.org\/10.1128\/AAC.03572-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR25","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing:M100. 31st ed.; 2021"},{"key":"720_CR26","unstructured":"European Committee on antimicrobial Susceptibility Testing, minimum inhibitory concentration (MIC) distributions and epidemiological cut-off values (ECOFFs); 2021. https:\/\/www.eucast.org\/clinical_breakpoints\/ Accessed 2 February 2022"},{"key":"720_CR27","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/AAC.00049-14","volume":"58","author":"C Lucasti","year":"2014","unstructured":"Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, et\u00a0al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane\u2013tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350\u20137. https:\/\/doi.org\/10.1128\/AAC.00049-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR28","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","volume":"75","author":"L Caro","year":"2020","unstructured":"Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, et\u00a0al. Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3 g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother. 2020;75:1546\u201353. https:\/\/doi.org\/10.1093\/jac\/dkaa049.","journal-title":"J Antimicrob Chemother"},{"key":"720_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12967-020-02381-1","volume":"18","author":"C Man\u00e9","year":"2020","unstructured":"Man\u00e9 C, Delmas C, Porterie J, Jourdan G, Verwaerde P, Marcheix B, et\u00a0al. Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane\/tazobactam: an ex vivo and in vivo study. J Transl Med. 2020;18:213. https:\/\/doi.org\/10.1186\/s12967-020-02381-1.","journal-title":"J Transl Med"},{"key":"720_CR30","unstructured":"ZERBAXATM (ceftolozane and tazobactam) for injection. Whitehouse Station, NJ: Full Prescribing Information. Merck Sharp & Dohme Corp 2014"},{"key":"720_CR31","doi-asserted-by":"publisher","unstructured":"Barza M. Principles of tissue penetration of antibiotics. J Antimicrob Chemother 1981;8;Suppl C:7\u201328. https:\/\/doi.org\/10.1093\/jac\/8.suppl_c.7","DOI":"10.1093\/jac\/8.suppl_c.7"},{"key":"720_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/s0009-9120(86)80054-6","volume":"19","author":"MG Bergeron","year":"1986","unstructured":"Bergeron MG. Tissue penetration of antibiotics. Clin Biochem. 1986;19:90\u2013100. https:\/\/doi.org\/10.1016\/s0009-9120(86)80054-6.","journal-title":"Clin Biochem"},{"key":"720_CR33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1128\/AAC.35.10.1947","volume":"35","author":"DE Nix","year":"1991","unstructured":"Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother. 1991;35:1947\u201352. https:\/\/doi.org\/10.1128\/AAC.35.10.1947.","journal-title":"Antimicrob Agents Chemother"},{"key":"720_CR34","doi-asserted-by":"publisher","unstructured":"Perea EJ. Ofloxacin concentrations in tissues involved in respiratory tract infections. J Antimicrob Chemother. 1990;26;Suppl D:55\u201360. https:\/\/doi.org\/10.1093\/jac\/26.suppl_D.55","DOI":"10.1093\/jac\/26.suppl_D.55"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00720-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00720-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00720-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:30:09Z","timestamp":1674448209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00720-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00720-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}